4553
TOWA PHARMACEUTICAL CO.,LTD.
東和薬品
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
154,900
Mar 2022
165,615
Mar 2023
208,859
Mar 2024
227,934
Mar 2025
259,594
Operating profit(million JPY)
Mar 2021
19,923
Mar 2022
19,205
Mar 2023
5,514
Mar 2024
17,647
Mar 2025
23,242
Operating profit margin(%)
Mar 2021
12.86
Mar 2022
11.6
Mar 2023
2.64
Mar 2024
7.74
Mar 2025
8.95
Profit before tax(million JPY)
Mar 2021
18,728
Mar 2022
22,246
Mar 2023
4,605
Mar 2024
24,459
Mar 2025
26,330
Profit(million JPY)
Mar 2021
13,958
Mar 2022
15,914
Mar 2023
2,201
Mar 2024
16,173
Mar 2025
18,986
Total assets(million JPY)
Mar 2021
245,668
Mar 2022
329,935
Mar 2023
371,347
Mar 2024
430,653
Mar 2025
470,823
Cash and cash equivalents(million JPY)
Mar 2021
22,915
Mar 2022
32,830
Mar 2023
24,257
Mar 2024
29,650
Mar 2025
45,460
Cash flows from operating activities(million JPY)
Mar 2021
12,008
Mar 2022
22,129
Mar 2023
2,544
Mar 2024
8,212
Mar 2025
23,401
Cash flows from investing activities(million JPY)
Mar 2021
-9,100
Mar 2022
-59,729
Mar 2023
-30,284
Mar 2024
-40,394
Mar 2025
-31,287
Cash flows from financing activities(million JPY)
Mar 2021
184
Mar 2022
46,540
Mar 2023
17,481
Mar 2024
35,407
Mar 2025
21,567
Return on equity(%)
Mar 2021
12.6
Mar 2022
12.8
Mar 2023
1.6
Mar 2024
11
Mar 2025
11.6
Equity ratio(%)
Mar 2021
47.5
Mar 2022
40.1
Mar 2023
36.9
Mar 2024
36.2
Mar 2025
36.5
Earnings per share(JPY per share)
Mar 2021
283.62
Mar 2022
323.36
Mar 2023
44.72
Mar 2024
328.59
Mar 2025
385.71
Net assets per share(JPY per share)
Mar 2021
2,369.21
Mar 2022
2,685.18
Mar 2023
2,781.17
Mar 2024
3,167.27
Mar 2025
3,486.4
Dividend per share(JPY per share)
Mar 2021
44
Mar 2022
60
Mar 2023
60
Mar 2024
60
Mar 2025
70
Payout ratio(%)
Mar 2021
15.51
Mar 2022
18.56
Mar 2023
134.17
Mar 2024
18.26
Mar 2025
18.15
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.